InspireMD Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics:

Total Revenue: $1.8 million, flat compared to Q2 2025.

International Revenue: $2.1 million, up 21% year-over-year, driven by strong demand for the CGuard stent platform.

Gross Profit: Loss of $0.8 million (negative 43.7% of revenue), impacted by a $734,000 credit for returned products and a $612,000 impairment charge.

Adjusted Gross Profit: $0.6 million when excluding recall-related impacts.

Operating Expenses: $13.7 million, a slight increase from $13.3 million in Q2 2025, primarily due to higher costs for the U.S. commercial team and development expenses.

Net Loss: $14.3 million or $0.17 per share, compared to a net loss of $13.2 million or $0.26 per share in Q2 2025.

Cash Position: $30.4 million as of June 30, 2026, down from $54.2 million at the end of 2025.

2Strategic Updates and Business Highlights:

The company is focused on four priorities: optimizing international business, advancing regulatory programs for U.S. market reentry, enhancing the CGuard Prime delivery system, and aligning the organization with these goals.

International business growth reflects strong physician adoption and demand for CGuard.

Progress on regulatory submissions for the CGuard Prime 80 platform for TCAR and the redesigned CGuard Prime 135 platform for CAS, with anticipated FDA approvals in Q4 2026.

Enrollment of the first patient in the CGUARDIANS III study for the next-generation SwitchGuard neuroprotection system.

3Forward Guidance and Outlook:

The company expects potential FDA approval for both TCAR and CAS platforms by the end of 2026, which would significantly expand their addressable market.

The timeline for CGuard Prime 135 market reentry is projected for the first half of 2027, with optimism for possible acceleration if regulatory conditions allow.

Anticipated restructuring will yield approximately $9 million in annual savings, with full impact expected by Q4 2026.

4Bad News, Challenges, or Points of Concern:

The voluntary recall of the CGuard Prime 135 system has negatively impacted revenue and gross profit margins.

The company incurred a significant impairment charge related to the recalled inventory.

Cash reserves have decreased significantly, raising concerns about financial flexibility in the near term.

The timeline for regulatory approvals has been adjusted, indicating potential delays in market reentry.

5Notable Q&A Insights:

Management emphasized the importance of maintaining strong relationships with physicians during the recall period, with positive anticipation for the product's return.

The company is focused on a leaner organizational structure while ensuring commercial readiness for the relaunch.

Questions regarding regulatory timelines revealed a cautious approach, with management highlighting the need for realistic expectations based on FDA interactions and testing requirements.

The SwitchGuard neuroprotection system is considered crucial for the TCAR strategy, enhancing overall market potential and revenue opportunities. Overall, while InspireMD is navigating challenges from the recall and financial pressures, the company is making strategic moves to position itself for future growth and regulatory success.